Abeona Therapeutics (NASDAQ:ABEO) Upgraded at StockNews.com

Abeona Therapeutics (NASDAQ:ABEO) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday.

Other research analysts have also issued reports about the stock. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of Abeona Therapeutics in a research note on Monday, November 25th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $18.00 price target on shares of Abeona Therapeutics in a research note on Tuesday, October 29th.

Abeona Therapeutics Trading Up 6.5 %

Shares of Abeona Therapeutics stock traded up $0.36 on Tuesday, reaching $5.86. The company had a trading volume of 352,384 shares, compared to its average volume of 301,177. The firm has a market cap of $254.73 million, a price-to-earnings ratio of -2.18 and a beta of 1.43. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.12 and a quick ratio of 6.12. The firm’s 50-day moving average price is $5.72 and its two-hundred day moving average price is $5.74. Abeona Therapeutics has a 1 year low of $3.05 and a 1 year high of $9.01.

Institutional Trading of Abeona Therapeutics

A number of large investors have recently made changes to their positions in ABEO. abrdn plc increased its holdings in Abeona Therapeutics by 158.8% during the 3rd quarter. abrdn plc now owns 326,995 shares of the biopharmaceutical company’s stock worth $2,067,000 after purchasing an additional 200,647 shares during the period. Rosalind Advisors Inc. lifted its holdings in shares of Abeona Therapeutics by 4.7% in the 3rd quarter. Rosalind Advisors Inc. now owns 1,832,000 shares of the biopharmaceutical company’s stock worth $11,578,000 after buying an additional 82,000 shares during the period. GSA Capital Partners LLP grew its position in shares of Abeona Therapeutics by 54.3% during the 3rd quarter. GSA Capital Partners LLP now owns 96,092 shares of the biopharmaceutical company’s stock worth $607,000 after buying an additional 33,831 shares in the last quarter. Charles Schwab Investment Management Inc. purchased a new position in shares of Abeona Therapeutics during the third quarter valued at $151,000. Finally, Citigroup Inc. raised its holdings in shares of Abeona Therapeutics by 10.1% in the third quarter. Citigroup Inc. now owns 616,668 shares of the biopharmaceutical company’s stock valued at $3,897,000 after acquiring an additional 56,332 shares in the last quarter. 80.56% of the stock is owned by hedge funds and other institutional investors.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.